Literature DB >> 2990682

Retroviruses associated with leukemia and ablative syndromes in animals and in human beings.

M Essex, M F McLane, P Kanki, J Allan, L Kitchen, T H Lee.   

Abstract

T-lymphotropic retroviruses of cats cause lymphopenia and immunosuppression and represent the major cause of death in that species. Similarly HTLV-I which is T4 tropic is associated with an increased risk for development of infectious disease in regions where the virus is endemic. Since HTLV-I is also believed to be transmitted by blood and by sexual intercourse we considered the possibility that a variant form of HTLV might cause AIDS. The identification of cross-reactive antibodies to HTLV-I-MA in a third or more of the AIDS patients and in suspicious blood donors that donated to transfusion-associated cases of AIDS eventually led to the recognition of HTLV-III, the causative agent of AIDS. The protein most associated with lymphocyte immortalization or transformation in the case of HTLV-I is p42. The proteins of HTLV-I encoded by the amino terminus of the env gene designated gp61 and gp45 are the most immunogenic antigens of this virus. Similarly those encoded by the amino terminus of the env gene HTLV-III designated gp160 and gp120 appear to be the most immunogenic markers for this agent. Almost all AIDS patients, ARC patients, and asymptomatic hemophiliacs have detectable antibodies to gp120 and gp160. HTLV-III related agents designated STLV-III have been found in macaque monkeys that develop simian AIDS and high prevalence rates of antibodies to STLV-III can be found in healthy African green monkeys. We hypothesize that the STLV-III of African green monkeys could represent a recent source of the virus to have infected humans in central Africa where the human epidemic probably began. The recognition that up to one million people may already be infected with HTLV-III in the United States alone indicates the need for development of a vaccine. The availability of primate species infected with the serologically related STLV-III agents that either resist disease development (African green monkeys) or succumb to an AIDS-type syndrome (rhesus) provide models that should aid in our attempts to develop such vaccines.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990682

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Suppressive effect on polyclonal B-cell activation of a synthetic peptide homologous to a transmembrane component of oncogenic retroviruses.

Authors:  M Mitani; G J Cianciolo; R Snyderman; M Yasuda; R A Good; N K Day
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

2.  In situ hybridization of feline leukemia virus in a primary neural B-cell lymphoma.

Authors:  Anna Szilasi; Lilla Dénes; Csaba Jakab; Ildikó Erdélyi; Talita Resende; Fabio Vannucci; Judit Csomor; Míra Mándoki; Gyula Balka
Journal:  J Vet Diagn Invest       Date:  2020-04-10       Impact factor: 1.279

3.  Unrecognized "AIDS" in Monkeys, 1969-1980: Explanations and Implications.

Authors:  Theodore M Hammett; Roderick T Bronson
Journal:  Am J Public Health       Date:  2016-04-14       Impact factor: 9.308

4.  Uterine adenocarcinoma with feline leukemia virus infection.

Authors:  Sung-Jin Cho; Hyun-A Lee; Sunhwa Hong; Okjin Kim
Journal:  Lab Anim Res       Date:  2011-12-19

5.  HIV and HTLV-I antibody studies: pregnant women in the 1960s, patients with AIDS, homosexuals, and individuals with tropical spastic paraparesis.

Authors:  D L Madden; N R Tzan; G C Roman; R Detels; F K Mundon; D A Fuccillo; J L Sever
Journal:  Yale J Biol Med       Date:  1987 Nov-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.